Clinical Trials · NCT03931915
Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- ASKA Pharmaceutical Co., Ltd.
- Enrollment
- 335
- Start date
- May 2019
- Locations
- 41 sites, Japan
- Primary endpoint
- Change of maximum Visual Analogue Scale (VAS) score for endometriosis associated pelvic pain